26 May 2020

The Radboud Biobank has added one new sub-biobank to the collection: HEMLYM.

The Hematology-Lymphoma Biobank plans to collect blood, saliva, serum and cell-free DNA from every lymphoma patient, in addition to the residual material available from the Pathology department (tumor tissue), the Hematology department and the Laboratory of Hematology (bone marrow, peripheral blood and tumor tissue). In recent years, much progress has been made in the knowledge surrounding the processes involved in the development and progression of lymph node cancer and the response to therapy. The aim and ambition of HEMLYM is to improve the diagnosis and treatment of patients with lymphoma.
 
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Biobanking: the power of collecting

26 May 2020

Urine, cerebrospinal fluid, blood. Everything is stored in Dutch biobanks. Collecting this takes a lot of time and money. Is it worth that? What does it yield?

read more

Costs for internal researchers in case of request for samples

26 May 2020

As of January 1, 2020, internal researchers who request samples from the Radboud Biobank will only be charged for the number of samples received.

read more

Biobank OPMD

25 February 2020

In oculopharyngeal muscular dystrophy (OPMD), muscle strength slowly decreases due to a breakdown of muscle cells. The Biobank OPMD contains clinical data and residual biomaterial.

read more

Biobank BVO

25 February 2020

The Biobank BVO contains left-over cytological material from the cervical screening program. The ambition of the BVO Biobank is to make this residual material available for scientific research.

read more

BBMRI-NL series on sustainable biobanking

25 February 2020

BBMRI-NL has made a series on sustainable biobanking, combining current knowledge from literature, workshops, and focus groups.

read more